Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JKB 122

Drug Profile

JKB 122

Alternative Names: JKB-122

Latest Information Update: 05 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jenken Biosciences
  • Developer Jenken Biosciences; TaiwanJ Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Antivirals; Hepatoprotectants; Small molecules
  • Mechanism of Action Immunomodulators; Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Autoimmune hepatitis; Crohn's disease; Hepatitis; Hepatitis C; Non-alcoholic fatty liver disease
  • No development reported Non-alcoholic steatohepatitis

Most Recent Events

  • 29 Aug 2023 Biostax Corp signs a research collaboration agreement with Immgenuity to focus on using JKB 122 and naltrexone with Immgenuity’s IMTV014 both independently and together to achieve remission with HIV patients
  • 20 Aug 2023 Immune Therapeutics accepts transfer of three IND applications for Nonalcoholic steatohepatitis (NASH), fibrosis, Nonalcoholic Liver Disease (NAFLD) and Autoimmune Hepatitis along with the Orphan Designation for Autoimmune Hepatitis from TaiwanJ Pharmaceuticals
  • 28 Jun 2023 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Taiwan (PO, Controlled release)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top